ReviewCancer2016
The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.
Review in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 98 citations in OpenAlex.
- Impact of a Multi-Level, Multi-Component, System Intervention on HPV Vaccination in a Federally Qualified Health Center.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Trial
- [Vaccine prevention of HPV-associated diseases].Dermatologie (Heidelberg, Germany) · 2026Review
- Redefining oropharyngeal cancer in the HPV era: integrating precision medicine and immunotherapeutic frontiers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Cancer Vaccines: Mechanisms, Clinical Applications, Challenges, and Future Directions in Precision Medicine.Current cancer drug targets · 2026Review
- Racial and ethnic disparities in human papillomavirus (HPV) vaccine uptake among United States adults, aged 27-45 years.Human vaccines & immunotherapeutics · 2024Article
- LRG1 and SDR16C5 protein expressions differ according to HPV status in oropharyngeal squamous cell carcinoma.Scientific reports · 2024Article
- Oral HPV Infection in Women with HPV-Positive Cervix Is Closely Related to Oral Sex.Diagnostics (Basel, Switzerland) · 2023Article
- The effectiveness of HPV vaccination on the incidence of oropharyngeal cancers in men: a review.Infectious agents and cancer · 2023Review
- Impact of HPV vaccination on HPV-related oral infections.Oral oncology · 2023Article
- Feasibility of clinical evaluation of individuals with increased risk for HPV-associated oropharynx cancer.Head & neck · 2023Article
- Reduced-dose radiation in human papillomavirus-associated oropharyngeal carcinoma can improve outcome: a systematic review and meta-analysis.Annals of translational medicine · 2022Article
- Trends in hospitalization and death rates among patients with head and neck cancer in Spain, 2009 to 2019.Human vaccines & immunotherapeutics · 2022Article
- Human Papillomavirus Infection and Oropharyngeal and Gastrointestinal Cancers: A Causal Relationship?Diseases (Basel, Switzerland) · 2022Review
- The Role of HPV in Determining Treatment, Survival, and Prognosis of Head and Neck Squamous Cell Carcinoma.Cancers · 2022Article
- Prevalence of oral human papillomavirus infection among Indian HIV-positive men who have sex with men: a cross-sectional study.BMC infectious diseases · 2021Article
- State of the art vaccination strategies as primary prevention to reduce incidence of gastrointestinal cancers.Journal of gastrointestinal oncology · 2021Review
- Retropharyngeal lymph node-sparing radiotherapy in patients with oropharyngeal carcinoma.Radiation oncology journal · 2021Article
- [Prevention of HPV-induced diseases by prophylactic vaccination].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Review
- Characterization of high risk human papilloma virus genotypes associated with oropharyngeal cancers in a Nigerian population.The Pan African medical journal · 2021Article
- Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The incidence of oropharyngeal cancer (OPC) is significantly increasing in the United States. Given that these epidemiologic trends are driven by human papillomavirus (HPV), the potential impact of prophylactic HPV vaccines on the prevention of OPC is of interest. The primary evidence supporting the approval of current prophylactic HPV vaccines is from large phase 3 clinical trials focused on the prevention of genital disease (cervical and anal cancer, as well as genital warts). These trials reported vaccine efficacy rates of 89% to 98% for the prevention of both premalignant lesions and persistent genital infections. However, these trials were designed before the etiologic relationship between HPV and OPC was established. There are differences in the epidemiology of oral and genital HPV infection, such as differences in age and sex distributions, which suggest that the vaccine efficacy observed in genital cancers may not be directly translatable to the cancers of the oropharynx. Evaluation of vaccine efficacy is challenging in the oropharynx because no premalignant lesion analogous to cervical intraepithelial neoplasia in cervical cancer has yet been identified. To truly investigate the efficacy of these vaccines in the oropharynx, additional clinical trials with feasible endpoints are needed. Cancer 2016;122:2313-2323. © 2016 American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.